Results 141 to 150 of about 313,244 (194)
A proimmunotoxin nanodrug targeting AIDS-associated non-Hodgkin lymphoma. [PDF]
Chen S +15 more
europepmc +1 more source
The development of a novel recombinant immunotoxin for the treatment of leukemia
openaire +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Breast Cancer Research and Treatment, 1996
Pseudomonas exotoxin has been genetically modified so that it targets cancer cells. This was accomplished by deleting its cell binding domain and replacing it with Fv fragments of antibodies that react with breast, colon, and other cancers. Several recombinant immunotoxins are now in clinical trials.
I, Pastan +3 more
openaire +2 more sources
Pseudomonas exotoxin has been genetically modified so that it targets cancer cells. This was accomplished by deleting its cell binding domain and replacing it with Fv fragments of antibodies that react with breast, colon, and other cancers. Several recombinant immunotoxins are now in clinical trials.
I, Pastan +3 more
openaire +2 more sources
Recombinant immunotoxins for cancer therapy
Expert Opinion on Biological Therapy, 2001Recombinant immunotoxins consist of Fv regions of tumour-selective antibodies fused to toxins found in bacteria, plants or fungi. These toxins must be modified to remove normal-tissue binding sites but to retain all other functions of cytotoxicity. The recombinant antibody fragments target the modified toxin to cancer cells which are killed, either by ...
U, Brinkmann +2 more
openaire +2 more sources
Immunotoxins and Recombinant Immunotoxins in Cancer Therapy
2006Targeted cancer therapy in general and immunotherapy in particular, combines rational drug design with the progress in understanding cancer biology. This approach takes advantage of our recent knowledge of the mechanisms by which normal cells are transformed into cancer cells, thus, using the special properties of cancer cells to device novel ...
Yoram Reiter, Avital Lev
openaire +1 more source
Recombinant immunotoxins for the treatment of cancer
Journal of Controlled Release, 1996The targeted delivery of protein toxins is presented as a novel approach for the treatment of human cancer. Bacterial or plant toxins are modified genetically to delete sequences that mediate binding to all cells. These sequences are replaced by cDNAs which encode binding ligands for receptors and antigens which are expressed selectively at high levels
David Fitzgerald, Ira Pastan
openaire +1 more source
Modeling Recombinant Immunotoxin Efficacies in Solid Tumors
Annals of Biomedical Engineering, 2008Effectiveness of cancer therapy is improved by the use of recombinant immunotoxins (RITs) that target membrane proteins unique to malignant tumor cells. Although RIT antitumor activity in vivo can always be improved with larger doses, clinical restriction on the dose toleration makes it critical to explore how RIT antitumor activity can be maximized ...
Kevin C, Chen +3 more
openaire +2 more sources
Immunotoxins and recombinant toxins in the treatment of solid carcinomas
The American Journal of Surgery, 1993Cancer remains the second most common cause of death in our society, and advanced disease is often refractory to surgical, chemotherapeutic, and radiologic interventions. One novel approach to cancer treatment involves targeting a cytotoxic agent to a cancer cell. Immunotoxins have been developed that contain a potent toxin (either Pseudomonas exotoxin,
C P, Theuer, I, Pastan
openaire +2 more sources
Responses in Refractory Hairy Cell Leukemia to a Recombinant Immunotoxin
Blood, 1999We report major responses in 4 of 4 patients with hairy cell leukemia (HCL) who have recently been treated on a phase I trial with the recombinant immunotoxin LMB-2. The immunotoxin, designed to target CD25+ malignancies, is composed of the Fv portion of the anti-Tac (anti-CD25) antibody, fused to a 38-kD truncated form of Pseudomonas exotoxin A, and ...
Robert J Kreitman +2 more
exaly +3 more sources

